Tumor‑suppressive effects of Smad‑ubiquitination regulator 2 in papillary thyroid carcinoma

Luo,Guirong; Zhang,Liting; Zhang,Lihong; Wu,Wenyi; Lin,Jianqing; Shi,Haihong; Yu,Yihuang; Qiu,Weigang; Chen,Jinyan; Ding,Hansen; Chen,Xinyao

doi:10.3892/ol.2024.14396

June-2024 Volume 27 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

June-2024 Volume 27 Issue 6

Full Size Image

Article

Tumor‑suppressive effects of Smad‑ubiquitination regulator 2 in papillary thyroid carcinoma

Authors:
- Guirong Luo
- Liting Zhang
- Lihong Zhang
- Wenyi Wu
- Jianqing Lin
- Haihong Shi
- Yihuang Yu
- Weigang Qiu
- Jinyan Chen
- Hansen Ding
- Xinyao Chen
View Affiliations / Copyright

Affiliations: Department of Thyroid and Breast Surgery, The Second Affiliated Clinical School of Medicine, Fujian Medical University, Quanzhou, Fujian 362000, P.R. China, Department of Endocrinology, No. 910th Hospital of The People's Liberation Army Joint Logistics Support Force, Quanzhou, Fujian 362000, P.R. China, Department of General Family Medicine, Jinshang Town Health Center, Quanzhou, Fujian 362000, P.R. China
Article Number: 263
|
Published online on: April 10, 2024

https://doi.org/10.3892/ol.2024.14396
Expand metrics +

Abstract

Smad‑ubiquitination regulator 2 (SMURF2) functions as a homolog of E6AP carboxyl terminus‑type E3 ubiquitin ligase to regulate cell cycle progression and tumor growth factor expression. SMURF2 has been revealed to function as a tumor suppressor in a number of cancers; however, its function in papillary thyroid carcinoma (PTC) remains largely unknown. Therefore, the aim of the present study was to investigate the function of SMURF2 in PTC. Reverse transcription‑quantitative PCR and western blotting were used to detect cellular expression of SMURF2 in vitro. After increasing or inhibiting the expression of SMURF2, MTT was used to detect the effect on tumor cell proliferation and Transwell assays were used to detect the effect on tumor cell migration and invasion. Finally, ELISA was used to detect the effects on glucose and glutamine metabolism in tumor cells and the findings revealed that SMURF2 was downregulated in PTC tissues. Moreover, SMURF2 inhibited the proliferation, invasion and migration of PTC cells, and promoted their apoptosis. Finally, SMURF2 inhibited cell glycolysis and glutaminolysis and affected metabolism in the PTC cell line, TPC‑1. Thus, the findings of the present study suggest that SMURF2 may be a potential target in the treatment of PTC.

View Figures

View References

1	Lim H, Devesa SS, Sosa JA, Check D and Kitahara CM: Trends in thyroid cancer incidence and mortality in the united states, 1974–2013. JAMA. 317:1338–1348. 2017. View Article : Google Scholar : PubMed/NCBI
2	Pu WL, Shi X, Yu PC, Zhang MY, Liu ZY, Tan L, Han P, Wang Y, Ji D, Gan H, et al: Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma. Nat Commun. 12:60582021. View Article : Google Scholar : PubMed/NCBI
3	Ilic N, Tao YL, Boutros-Suleiman S, Kadali VN, Emanuelli A, Levy-Cohen G and Blank M: SMURF2-mediated ubiquitin signaling plays an essential role in the regulation of PARP1 PARylating activity, molecular interactions, and functions in mammalian cells. FASEB J. 35:e214362021. View Article : Google Scholar : PubMed/NCBI
4	Blank M, Tang Y, Yamashita M, Burkett SS, Cheng SY and Zhang YE: A tumor suppressor function of Smurf2 associated with controlling chromatin landscape and genome stability through RNF20. Nat Med. 18:227–234. 2012. View Article : Google Scholar : PubMed/NCBI
5	Li YK, Yang DQ, Tian N, Zhang P, Zhu YM, Meng J, Feng M, Lu Y, Liu Q, Tong L, et al: The ubiquitination ligase SMURF2 reduces aerobic glycolysis and colorectal cancer cell proliferation by promoting ChREBP ubiquitination and degradation. J Biol Chem. 294:14745–14756. 2019. View Article : Google Scholar : PubMed/NCBI
6	Song DQ, Li SY, Ning LX, Zhang SC and Cai Y: Smurf2 suppresses the metastasis of hepatocellular carcinoma via ubiquitin degradation of Smad2. Open Med (Wars). 17:384–396. 2022. View Article : Google Scholar : PubMed/NCBI
7	Yu L, Dong L, Wang Y, Liu L, Long H, Li H, Li J, Yang X, Liu Z, Duan G, et al: Reversible regulation of SATB1 ubiquitination by USP47 and SMURF2 mediates colon cancer cell proliferation and tumor progression. Cancer Lett. 448:40–51. 2019. View Article : Google Scholar : PubMed/NCBI
8	Li Z and Zhang H: Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Biochim Biophys Acta Rev Cancer. 73:377–392. 2016.
9	Sun LC, Suo CX, Li ST, Zhang HF and Gao P: Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect. Biochim Biophys Acta Rev Cancer. 1870:51–66. 2018. View Article : Google Scholar : PubMed/NCBI
10	Liu Y, Zhou Q, Song SL and Tang S: Integrating metabolic reprogramming and metabolic imaging to predict breast cancer therapeutic responses. Trends Endocrinol Metab. 32:762–775. 2021. View Article : Google Scholar : PubMed/NCBI
11	Coelho RG, Fortunato RS and Carvalho DP: Metabolic reprogramming in thyroid carcinoma. Front Oncol. 8:822018. View Article : Google Scholar : PubMed/NCBI
12	Cameselle-Teijeiro JM: Changes and perspectives in the New 2022 WHO classification of thyroid neoplasms. Rev Esp Patol. 55:145–148. 2022.(In Spanish). PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Sun T, Liu Z and Yang Q: The role of ubiquitination and deubiquitination in cancer metabolism. Mol Cancer. 19:1462020. View Article : Google Scholar : PubMed/NCBI
15	Bedford L, Lowe J, Dick LR, Mayer RJ and Brownell JE: Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov. 10:29–46. 2011. View Article : Google Scholar : PubMed/NCBI
16	Sun TS, Liu ZN and Yang Q: The role of ubiquitination and deubiquitination in cancer metabolism. Mol Cancer. 19:1462020. View Article : Google Scholar : PubMed/NCBI
17	Fan Q, Wang Q, Cai RJ, Yuan HH and Xu M: The ubiquitin system: Orchestrating cellular signals in non-small-cell lung cancer. Cell Mol Biol Lett. 25:12020. View Article : Google Scholar : PubMed/NCBI
18	Gao QF, Wang SC and Zhang ZY: E3 ubiquitin ligase SMURF2 prevents colorectal cancer by reducing the stability of the YY1 protein and inhibiting the SENP1/c-myc axis. Gene Ther. 30:51–63. 2023. View Article : Google Scholar : PubMed/NCBI
19	Tan YW, Chen YJ, Du MG, Peng ZQ and Xie P: USF2 inhibits the transcriptional activity of Smurf1 and Smurf2 to promote breast cancer tumorigenesis. Cell Signal. 53:49–58. 2019. View Article : Google Scholar : PubMed/NCBI
20	Chaudhary KR, Kinslow CJ, Cheng HY, Silva JM, Yu JY, Wang TJ, Hei TK, Halmos B and Cheng SK: Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer. Sci Rep. 12:101402022. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Tumor‑suppressive effects of Smad‑ubiquitination regulator 2 in papillary thyroid carcinoma

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles